![]() ![]() HiTrap Capto Q, HiTrap Capto S and HiTrap Capto DEAE are prepacked 1 mL and 5 mL columns for screening of selectivity, binding and elution conditions, as well as small scale purifications. This method enabled > 90 % overall recovery of unformulated DS at ≥ 150 g/L. Capto Q, Capto S and Capto DEAE are ion exchange BioProcess resins for capture and intermediate purification of proteins. Most of the rinse was combined with the retentate to hit the target protein concentration. TOYOPEARL GigaCap S-650M resin is a high capacity cation exchange resin optimized for the capture and purification of both small and large proteins. After the retentate was collected, a minimal volume of buffer was added for the UF rinse. During the UF/DF process, the antibody was initially concentrated to 90 g/L, diafiltered, and concentrated to ≥ 180 g/L, then the retentate was collected. Analysis showed that the Capto S run removed the excipients with yields of ≥ 96%. Trade Name: Acezide, Capozide, Capto-Co, Alopresin Diu, Ecazide. In addition, Capto S has lower resin costs, takes less time to process, and uses milder elution conditions. Epivir, Zeffix, Lamivir, Lamivir S-30, Tenvir-L, Epivir-HBV, Temixys, Acriptega. A Capto S column was chosen over Protein A chromatography to remove excipients from formulated drug substance because of its higher binding capacity. Diminum saat perut kosong, 1 jam sebelum makan atau 2 jam setelah makan. Fortunately, a sufficient supply of formulated DS was available for reprocessing. Since the pilot plants were not available for large-scale campaigns, a creative alternative was needed to produce 2 kg of antibody from formulated DS for these studies. ImpRes (Cytiva) and HiScreen Capto S ImpAct. During process scale-up, the project team decided to make a high-concentration mAb drug substance for subcutaneous injection and change the formulation. chymotrypsinogen A are presented using the prepacked columns GoBio Screen 7x100 40S, HiScreen Capto SP. The scope of this work is two-fold: 1) excipients removal from formulated mAb drug substance by Capto S chromatography and 2) UF/DF process development to make high-concentration drug substance (DS) for subcutaneous injection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |